Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Innocan Pharma Corp C.INNO

Alternate Symbol(s):  INNPF

Healthcare
Innocan Pharma Corporation is an Israel-based pharmaceutical company active in the medical cannabis industry. It operates through three distinct operating segments: Research, Development, Marketing, Distribution and sales of InnoCan-branded over the counter (OTC) pharmaceutical products; Research and Development of Non-pharmaceutical products for third parties and Research and Development of... see more

Recent & Breaking News (CSE:INNO)

Innocan Pharma Unveils Groundbreaking Veterinary Breakthroughs at EAVPT 2023 Congress

Canada NewsWire June 22, 2023

Innocan Pharma Reports Q1 2023 Results including US$1.3M Increase in Revenues Compared to Q1 2022

Canada NewsWire May 31, 2023

Innocan Pharma Reports Success in a Pre-Clinical Trial of a Liposomal-CBD Injection on a Paralyzed Goat

Canada NewsWire May 8, 2023

Innocan Pharma Announces 5000 Units Sale and Expansion to Lithuania, Latvia & Estonia Markets

Canada NewsWire May 1, 2023

Innocan Pharma Reports Annual 2022 Results with USD 2.6M in Revenue

Canada NewsWire April 18, 2023

Innocan Reports Novel Cannabinoid Delivery Platform Patent Application

Canada NewsWire April 3, 2023

Innocan Pharma (CSE:INNO) reports successful efficacy test for vaginal derma product

Maor Kagan March 23, 2023

Innocan Pharma Reports Successful Results of Efficacy Test for Vaginal Derma Product

Newsfile March 23, 2023

Innocan Pharma (CSE:INNO) to launch CBD veterinary commercialization team

Shoran Devi March 17, 2023

Innocan Pharma Announces Launch of CBD Veterinary Commercialization Team

Newsfile March 17, 2023

Ripples of Silicon Valley Bank's collapse felt at the TSX

Azuka Onwuka March 13, 2023

Innocan Pharma (CSE:INNO) secures first U.S. patent

Azuka Onwuka March 13, 2023

Innocan Pharma Announces First Patent Grant in the United States

Newsfile March 12, 2023

Innocan Pharma Reports Clinical Success in Canine Compassionate Care Trial

Newsfile February 21, 2023

Innocan Pharma Provides Annual "State of the Business" Update

Newsfile February 16, 2023

Innocan Pharma Signs a First Consulting Agreement to Commercialize its Pharmaceutical IP in the Veterinary Field

Newsfile December 2, 2022

Innocan Pharma (CSE:INNO) reports Q3 2022 results

John Ballem  November 29, 2022

Innocan Pharma Reports Q3 2022 Results with 700% Increase in Revenues Compared to Q3 2021

Newsfile November 29, 2022

Mr. Givi Topchishvili to Join Innocan Pharma's Advisory Committee

Newsfile November 18, 2022

Canadian Securities Exchange Reports October 2022 Performance Figures

Newsfile November 15, 2022